Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Cash from Operations came in at 47195000.0 in Q2 2026, up 68.01% YoY from 28090000.0 in Q2 2025, and down 5.98% on a QoQ basis from 50199000.0 in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Cash from Operations data on file, last reported at 47195000.0 in Q2 2026.
- Quarterly Cash from Operations rose 68.01% year-over-year to 47195000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 184965000.0 (up 176.28% YoY) and the FY2025 annual result came in at 137985000.0, up 437.14% from the prior year.
- Cash from Operations declined to 47195000.0 in Q2 2026, from 50199000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 62053000.0 in Q3 2022 to a low of 36846000.0 in Q1 2022.
- A 5-year average of 15565333.33 and a median of 11077000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 113.16% — and 2025, when it jumped 1606.13%.
- Tracing KNSA's Cash from Operations over 5 years: stood at 11576000.0 in 2022, then surged by 137.36% to 4325000.0 in 2023, then soared by 333.99% to 18770000.0 in 2024, then surged by 187.13% to 53894000.0 in 2025, then dropped by 12.43% to 47195000.0 in 2026.
- The last three Cash from Operations figures came in at 47195000.0 (Q2 2026), 50199000.0 (Q1 2026), and 53894000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.04 Bn | 5.52 Bn | 220.03 Mn | 47.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.20 Mn |
| Jun 30, 2026 | 47.20 Mn |
| Mar 31, 2026 | 50.20 Mn |
| Mar 31, 2026 | 50.20 Mn |
| Dec 31, 2025 | 53.89 Mn |
| Dec 31, 2025 | 53.89 Mn |
| Sep 30, 2025 | 33.68 Mn |
| Sep 30, 2025 | 33.68 Mn |
| Jun 30, 2025 | 28.09 Mn |
| Jun 30, 2025 | 28.09 Mn |
| Mar 31, 2025 | 22.32 Mn |
| Mar 31, 2025 | 22.32 Mn |
| Dec 31, 2024 | 18.77 Mn |
| Dec 31, 2024 | 18.77 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Jun 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 5.17 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Mar 31, 2024 | 3.99 Mn |